ICML 2017 | Key misconceptions about biosimilars
Won Seog Kim, MD, PhD from Sungkyunkwan University, Seoul, South Korea discusses misconceptions about biosimilars at the International Conference on Malignant Lymphoma (ICML) 2017 in Lugano, Switzerland. A common misconception from healthcare personnel is that biosimilar drugs are not identical, but very similar. The safety and efficacy of biosimilars are ensured through clinical trials, and he gives the example of rituximab. He states that there are currently no concerns regarding the use of biosimilars in the hematology-oncology field. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.
Get great new content delivered to your inboxSign up